Skip to main content
Clinical Trials/NL-OMON50922
NL-OMON50922CompletedPhase 4

Effect of oral magnesium supplementation on insulin sensitivity in people with type 2 diabetes - Magnesium

Radboud Universitair Medisch Centrum0 sites14 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
14

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • •* Clinical diagnosis of type 2 diabetes mellitus
  • •* Treatment with insulin for at least one year
  • •* Minimum age of 18 years
  • •* Ability to provide informed consent

Exclusion Criteria

  • •* Treatment with more than 7.5 mg prednisone daily (or a comparable dose of
  • •other oral corticosteroids)
  • •* Use of magnesium supplementation in the week before screening
  • •* Any cardiovascular event in the six months before screening
  • •* Illnesses and unstable diseases that interfere with the primary outcome
  • •* Chronic diarrhea
  • •* Alcohol consumption of more than 14 units weekly
  • •* MDRD-GFR < 45 ml/min/1.73m2
  • •* Body-Mass Index < 18 or > 40 kg/m2
  • •* Pregnancy or the wish to become pregnant

Investigators

Similar Trials

Effect of oral magnesium supplementation... | Clinical Trial